23 Nov

ResApp completes COVID-19 study recruitment in India

ResApp Health Limited ABN 51 094 468 318 Level 12 , 100 Creek St, Brisbane QLD 4000 Australia T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au ResApp completes COVID - 19 study recruitment in India • ResApp’s Indian COVID - 19 study has completed recruitment of 337 patients, including over 200 COVID - 19 positive cases • ResApp ’ s US study has recruited its first patient f rom in - person COVID - 19 testing clinic • ResApp is using data collected in these studies to develop and train machine learning algorithms to identify COVID - 19 from cough sounds recorded on a smartph one Brisbane, Australia, 2 3 November 20 2 1 – Re sApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease , is pleased to advise that it has completed recruitment in its COVID - 19 study in India . ResApp will use this data to develop a smartp hone - based algorithm to instantly screen for COVID - 19 and monitor disease progression. ResApp’s Indian COVID - 19 study ( Clinical Trials Registry – India: CTRI/2021/09/036581) has recruited 337 patients, including over 2 00 COVID - 19 positive cases , across two study arms in India. Both positive and negative cases were confirmed with gold standard polymerase chain reaction (PCR) pathology testing. O utpatients and inpatients were recrui ted, with inpatients additionally providing cough sound samples at multiple times during their hospital stay to understand more about disease progression ResApp’s US based study ( clinicaltrials.gov: NCT04864535 ) has recently been expanded to allow recruitment from in - person COVID - 19 testing clinics in addition to its existing at - home recruitment. ResApp advi s es that the first patient has now been recruited in the in - person testing clinic arm of the study. Recruitm ent in the US study is expected to complete mid - December 2021. CEO and Managing Director, Dr Tony Keating said: “ We are pleased to report that we have completed recruitment in India ahead of schedule . We are grateful to all the patients for their willingn ess to participate in the study, as well as the investigators and their teams for their hard work. This is an important milestone in collecting a high - quality dataset to perform the necessary development work to build , train and test machine learning algorithms capable of identifying COVID - 19 from cough sounds . “Europe i s the midst of a fourth wave of COVID - 19 pandemic bringing with it new lockdowns and increased hospitalisation rates. E xperts agree that screening and management of COVID - 19 will be an ongoing requirement for many years and ResApp is focused on the development of instant smartphone - based applications to fulfill these global need s . ” About ResApp Health Limited ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine ResApp Health Limited ABN 51 094 468 318 Level 12 , 100 Creek St, Brisbane QLD 4000 Australia T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au learning algorithms use sound to diagnose and measure the severity of resp iratory conditions without the need for additional accessories or hardware. ResApp’s regulatory - approved and clinically validated products include ResAppDx, a smartphone - based acute respiratory disease diagnostic test for use in telehealth, emergency depar tment and primary care settings; and SleepCheck, a smartphone application which allows consumers to self - assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au . Contacts Dr Tony Keating CEO and Managing Director +61 430 180 659 tony@resapphealth.com.au Mr Brian Leedman Executive Director , Corporate Affairs +61 412 281 780 brian@resapphealth.com.au This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Resapp Health (ASX:RAP) when you join Listcorp.